Infliximab is a chimeric human-murine monoclonal antibody capable of neutralizing both free and membrane-bound TNFa. It has been used as a TNF suppressor in MDS patients.50 Infliximab was given to 37 low-risk MDS patients in two cohorts: 5 and 10 mg/kg intravenously every 4 weeks for four cycles. Twenty-eight patients completed the four cycles. Infliximab successfully produced a variety of responses in about 20% of low- to intermediate-risk MDS patients, including multilineage responses.

0 0

Post a comment